ammonium hydroxide has been researched along with Cognitive Decline in 7 studies
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 5.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| "Minimal hepatic encephalopathy (MHE) reflects cognitive impairment in patients with liver cirrhosis and is associated with poor prognosis." | 3.30 | Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double-blind randomized controlled trial. ( Bara, S; Dalal, A; Kumar, A; Mahajan, B; Maharshi, S; Sachdeva, S; Sharma, A; Sharma, BC; Sonika, U; Srivastava, S, 2023) |
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 1.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| "Psychometric Hepatic Encephalopathy Score (PHES) and ammonia improved significantly in the patients with amelioration in SMI >10% (n = 16) and not in those without (n = 11) (PHES: -1." | 1.51 | The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. ( Gioia, S; Lattanzi, B; Merli, M; Nardelli, S; Pitocchi, F; Ridola, L; Riggio, O, 2019) |
| "We analyzed the presence of mild cognitive impairment (CI) by using the PHES battery of psychometric tests and measured the levels of ammonia and of the inflammatory cytokines IL-6 and IL-18 in blood of patients with different types of liver or dermatological diseases resulting in different grades of hyperammonemia and/or inflammation." | 1.38 | Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. ( Cassinello, N; Civera, M; Felipo, V; Garcia-Torres, ML; Jordá, E; Martinez-Valls, J; Molina, I; Montesinos, E; Montoliu, C; Olmo, JA; Ortega, J; Serra, MA; Urios, A; Wassel, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Szczygieł-Pilut, EE | 1 |
| Zajączkowska-Dutkiewicz, A | 1 |
| Pilut, D | 1 |
| Dutkiewicz, J | 1 |
| Sharma, BC | 1 |
| Maharshi, S | 1 |
| Sachdeva, S | 1 |
| Mahajan, B | 1 |
| Sharma, A | 1 |
| Bara, S | 1 |
| Srivastava, S | 1 |
| Kumar, A | 1 |
| Dalal, A | 1 |
| Sonika, U | 1 |
| Zhang, Y | 1 |
| Tan, SL | 1 |
| Du, J | 1 |
| Chen, Y | 1 |
| Jia, J | 1 |
| Feng, JG | 1 |
| Liu, KX | 1 |
| Zhou, J | 1 |
| Hadjihambi, A | 1 |
| Arias, N | 1 |
| Sheikh, M | 1 |
| Jalan, R | 1 |
| García-García, R | 1 |
| Cruz-Gómez, ÁJ | 1 |
| Mangas-Losada, A | 1 |
| Urios, A | 2 |
| Forn, C | 1 |
| Escudero-García, D | 1 |
| Kosenko, E | 1 |
| Ordoño, JF | 1 |
| Tosca, J | 1 |
| Giner-Durán, R | 1 |
| Serra, MA | 2 |
| Avila, C | 1 |
| Belloch, V | 1 |
| Felipo, V | 2 |
| Montoliu, C | 2 |
| Gioia, S | 1 |
| Merli, M | 1 |
| Nardelli, S | 1 |
| Lattanzi, B | 1 |
| Pitocchi, F | 1 |
| Ridola, L | 1 |
| Riggio, O | 1 |
| Montesinos, E | 1 |
| Molina, I | 1 |
| Garcia-Torres, ML | 1 |
| Civera, M | 1 |
| Olmo, JA | 1 |
| Ortega, J | 1 |
| Martinez-Valls, J | 1 |
| Cassinello, N | 1 |
| Wassel, A | 1 |
| Jordá, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Expanding the Therapeutic Landscape of Post-TIPS Hepatic Encephalopathy[NCT05346029] | 140 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ammonium hydroxide and Cognitive Decline
| Article | Year |
|---|---|
Hepatic encephalopathy: a critical current review.
Topics: Albumins; Ammonia; Anti-Bacterial Agents; Bile Acids and Salts; Brain; Brain Edema; Cognitive Dysfun | 2018 |
1 trial available for ammonium hydroxide and Cognitive Decline
| Article | Year |
|---|---|
Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double-blind randomized controlled trial.
Topics: Adult; Ammonia; Cognitive Dysfunction; Endotoxins; Hepatic Encephalopathy; Humans; Liver Cirrhosis; | 2023 |
5 other studies available for ammonium hydroxide and Cognitive Decline
| Article | Year |
|---|---|
HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY.
Topics: Ammonia; Anticonvulsants; Cognitive Dysfunction; Dementia; Epilepsy; Female; Humans; Hyperammonemia; | 2022 |
Dexmedetomidine alleviates neuroinflammation, restores sleep disorders and neurobehavioral abnormalities in rats with minimal hepatic encephalopathy.
Topics: Adrenergic alpha-2 Receptor Agonists; Ammonia; Animals; Anti-Inflammatory Agents; Anxiety; Behavior, | 2021 |
Reduced resting state connectivity and gray matter volume correlate with cognitive impairment in minimal hepatic encephalopathy.
Topics: Aged; Aged, 80 and over; Ammonia; Area Under Curve; Case-Control Studies; Cognitive Dysfunction; Cyc | 2017 |
The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS.
Topics: Ammonia; Cognitive Dysfunction; Female; Hepatic Encephalopathy; Humans; Italy; Liver Cirrhosis; Male | 2019 |
Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Cognitive Dysfunction; Fatty Liver; Female; Hepatic Encephalopathy; Humans; Hy | 2012 |